DUBLIN–(BUSINESS WIRE)–The “Artificial Intelligence in Drug Discovery Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The Global Artificial Intelligence in Drug Discovery Market is projected to reach USD 2,760.77 million by 2027 from USD 701.05 million in 2021, at a CAGR 25.66% during the forecast period.
In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.
The report on artificial intelligence in drug discovery identifies key attributes about the customer to define the potential market and identify different needs across the industry.
Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience.
This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.
Report Highlights
- The Americas Artificial Intelligence in Drug Discovery Market size was estimated at USD 286.37 million in 2021 and expected to reach USD 351.96 million in 2022, at a CAGR 25.24% to reach USD 1,105.52 million by 2027.
- The Asia-Pacific Artificial Intelligence in Drug Discovery Market size was estimated at USD 160.88 million in 2021 and expected to reach USD 203.34 million in 2022, at a CAGR 26.39% to reach USD 656.12 million by 2027.
- The Europe, Middle East & Africa Artificial Intelligence in Drug Discovery Market size was estimated at USD 253.79 million in 2021 and expected to reach USD 315.02 million in 2022, at a CAGR 25.65% to reach USD 999.12 million by 2027.
Company Usability Profiles:
- Aria Pharmaceuticals
- Atomwise, Inc.
- BenevolentAI Limited
- BioSymetrics Inc.
- Cloud Pharmaceuticals, Inc.
- Cyclica Inc.
- Deep Genomics Incorporated
- Envisagenics, Inc.
- Exscientia
- Insitro, Inc.
- International Business Machines Corporation
- Microsoft Corporation
- Novartis AG
- NVIDIA Corporation
- Owkin, Inc.
- Verge Genomics Inc.
- XtalPi Inc.
Market Segmentation & Coverage:
Offering:
- Services
- Software
Application:
- Cardiovascular Disease
- Immuno-Oncology
- Metabolic Diseases
- Neurodegenerative Diseases
End User:
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Research Centers and Academic & Government Institutes
Region:
-
Americas
- Argentina
- Brazil
- Canada
- Mexico
-
United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
-
Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
-
Europe, Middle East & Africa
- France
- Germany
- Italy
- Netherlands
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- United Arab Emirates
- United Kingdom
For more information about this report visit https://www.researchandmarkets.com/r/gg2m2m
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900